B-RAF: A contributor to the melanoma phenotype

International Journal of Biochemistry and Cell Biology

Volumn 43, Issue 1, 2011, Pages 29-32

  Heath, E M L ^a   Kaufman, K L ^a   Christopherson, R I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

B RAF; Melanoma; RAS RAF MEK ERK pathway

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; CHIR 265; MITOGEN ACTIVATED PROTEIN KINASE; PLX 4720; RAS PROTEIN; SMALL INTERFERING RNA; SORAFENIB; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; GENE STRUCTURE; HUMAN; MELANOCYTE; MELANOMA; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS;

EID: 78650243286     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2010.09.015     Document Type: Short Survey

References (29)

1. K.V. Bhatt, L.S. Spofford, G. Aram, M. McMullen, K. Pumiglia, and A.E. Aplin Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling Oncogene 24 2005 3459 3471
2. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
3. N. Dhomen, J.S. Reis-Filho, S. da Rocha Dias, R. Hayward, K. Savage, and V. Delmas Oncogenic Braf induces melanocyte senescence and melanoma in mice Cancer Cell 15 2009 294 303
4. L.A. Fecher, R. Amaravadi, and L.M. Schuchter Effectively targeting BRAF in melanoma: a formidable challenge Pigment Cell Melanoma Res 21 2008 410 411
5. K.T. Flaherty Sorafenib: delivering a targeted drug to the right targets Expert Rev Anticancer Ther 7 2007 617 626
6. M.J. Garnett, and R. Marais Guilty as charged: B-RAF is a human oncogene Cancer Cell 6 2004 313 319
7. V. Gray-Schopfer, C. Wellbrock, and R. Marais Melanoma biology and new targeted therapy Nature 445 2007 851 857
8. V.C. Gray-Schopfer, S. da Rocha Dias, and R. Marais The role of B-RAF in melanoma Cancer Metastasis Rev 24 2005 165 183
9. K.L. Guan, C. Figueroa, T.R. Brtva, T. Zhu, J. Taylor, and T.D. Barber Negative regulation of the serine/threonine kinase B-Raf by Akt J Biol Chem 275 2000 27354 27359
10. E. Halilovic Therapeutic strategies for inhibiting oncogenic BRAF signaling Curr Opin Pharmacol 2008 8
11. K.P. Hoeflich, D.C. Gray, M.T. Eby, J.Y. Tien, L. Wong, and J. Bower Oncogenic BRAF is required for tumor growth and maintenance in melanoma models Cancer Res 66 2006 999 1006
12. S. Ikawa, M. Fukui, Y. Ueyama, N. Tamaoki, T. Yamamoto, and K. Toyoshima B-raf, a new member of the raf family, is activated by DNA rearrangement Mol Cell Biol 8 1988 2651 2654
13. M. Kohno, and J. Pouyssegur Targeting the ERK signaling pathway in cancer therapy Ann Med 38 2006 200 211
14. J. Liu, K.G.S. Kumar, D. Yu, S.A. Molton, M. McMahon, and M. Herlyn Oncogenic BRAF regulates beta-Trcp expression and NF-kappa B activity in human melanoma cells Oncogene 26 2007 1954 1958
15. R. Loewe, H. Kittler, G. Fischer, I. Fae, K. Wolff, and P. Petzelbauer BRAF kinase gene V599E mutation in growing melanocytic lesions J Invest Dermatol 123 2004 733 736
16. P. Lopez-Bergami, B. Fitchman, and Z. Ronai Understanding signaling cascades in melanoma Photochem Photobiol 84 2008 289 306
17. P. Lopez-Bergami, C. Huang, J.S. Goydos, D. Yip, M. Bar-Eli, and M. Herlyn Rewired ERK-JNK signaling pathways in melanoma Cancer Cell 11 2007 447 460
18. R. Marais, and C.J. Marshall Control of the ERK MAP kinase cascade by Ras and Raf Cancer Surv 27 1996 101 125
19. M.J. Martin, D. Carling, and R. Marais Taking the stress out of melanoma Cancer Cell 15 2009 163 164
20. M.M. McCarthy, E. Pick, Y. Kluger, B. Gould-Rothberg, R. Lazova, and R.L. Camp HSP90 as a marker of progression in melanoma Ann Oncol 19 2008 590 594
21. U. McDermott, S.V. Sharma, L. Dowell, P. Greninger, C. Montagut, and J. Lamb Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling Proc Natl Acad Sci USA 104 2007 19936 19941
22. K. Omholt, A. Platz, L. Kanter, U. Ringborg, and J. Hansson NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression Clin Cancer Res 9 2003 6483 6488
23. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310
24. K. Satyamoorthy, G. Li, M.R. Gerrero, M.S. Brose, P. Volpe, and B.L. Weber Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation Cancer Res 63 2003 756 759
25. A. Sharma, N.R. Trivedi, M.A. Zimmerman, D.A. Tuveson, C.D. Smith, and G.P. Robertson Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors Cancer Res 65 2005 2412 2421
26. D.B. Solit, L.A. Garraway, C.A. Pratilas, A. Sawai, G. Getz, and A. Basso BRAF mutation predicts sensitivity to MEK inhibition Nature 439 2006 358 362
27. C. Wellbrock, M. Karasarides, and R. Marais The RAF proteins take centre stage Nat Rev Mol Cell Biol 5 2004 875 885
28. C. Wellbrock, L. Ogilvie, D. Hedley, M. Karasarides, J. Martin, and D. Niculescu-Duvaz V599EB-RAF is an oncogene in melanocytes Cancer Res 64 2004 2338 2342
29. C. Wellbrock, S. Rana, H. Paterson, H. Pickersgill, T. Brummelkamp, and R. Marais Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF PLoS One 3 2008 e2734